Addendum
Belzutifan (renal cell carcinoma) – Addendum to Project A25-45
Report documents
-
Addendum
Belzutifan (renal cell carcinoma) – Addendum to Project A25-45
Dossier assessment
Indication:
Adult patients with advanced clear cell renal cell carcinoma that has progressed following 2 or more lines of therapy that included a PD‑(L)1 inhibitor and at least 2 vascular endothelial growth factor‑targeted therapies
Result of dossier assessment:
- Patients < 65 years of age for whom everolimus is a suitable individualized treatment: unchanged after addendum: hint of a minor added benefit
- Patients ≥ 65 years of age for whom everolimus is a suitable individualized treatment: unchanged after addendum: hint of a considerable added benefit
- Patients for whom everolimus is not a suitable individualized treatment: unchanged after addendum: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2025-09-18 A G-BA decision was published.
Project details
- Project no.
- A25-107
- Commission
- Commission awarded on 12.08.2025 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent relevant page on the extent of the added benefit concludes the early benefit assessment.
- DOI
https://doi.org/10.60584/A25-107_en
Connected Projects
-
Dossier assessment
Belzutifan (renal cell carcinoma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed